Matches in Wikidata for { <http://www.wikidata.org/entity/Q66078394> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- Q66078394 description "assaig clínic" @default.
- Q66078394 description "clinical trial" @default.
- Q66078394 description "clinical trial" @default.
- Q66078394 description "clinical trial" @default.
- Q66078394 description "clinical trial" @default.
- Q66078394 description "ensaio clínico" @default.
- Q66078394 description "ensayo clínico" @default.
- Q66078394 description "ensayu clínicu" @default.
- Q66078394 description "essai clinique" @default.
- Q66078394 description "klinisch onderzoek" @default.
- Q66078394 description "клінічне випробування" @default.
- Q66078394 name "Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)" @default.
- Q66078394 name "Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia" @default.
- Q66078394 type Item @default.
- Q66078394 label "Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)" @default.
- Q66078394 label "Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia" @default.
- Q66078394 prefLabel "Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)" @default.
- Q66078394 prefLabel "Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia" @default.
- Q66078394 P1050 Q66078394-296B5698-8F3D-42C8-A960-3B9C4E889967 @default.
- Q66078394 P1132 Q66078394-00B2B59B-365C-400E-850B-CED1F34E06AA @default.
- Q66078394 P1476 Q66078394-6592D38F-8247-47FE-B56D-8165B02096DB @default.
- Q66078394 P17 Q66078394-35C84DA5-9F22-4603-922F-B36A9DA2D9B5 @default.
- Q66078394 P17 Q66078394-51F8C25F-5D6F-4B55-9307-43A18CB63044 @default.
- Q66078394 P17 Q66078394-62C7ABDD-3296-4C99-8C73-A6DC4E5E4B96 @default.
- Q66078394 P17 Q66078394-B4E3BF0B-321A-4F77-9EE5-3B1A1F3F8F96 @default.
- Q66078394 P17 Q66078394-DB5BF109-7F39-4527-8D95-E655A5B8B118 @default.
- Q66078394 P17 Q66078394-DD5D37F0-5998-4ECA-B82A-7600EBA15AA0 @default.
- Q66078394 P17 Q66078394-E99C9046-2835-4F0D-AC3E-F68BD55A3300 @default.
- Q66078394 P17 Q66078394-F167E7E9-3317-4460-9F44-080CD2BCCE3F @default.
- Q66078394 P2899 Q66078394-08D81068-FCFB-45B3-AA18-BAF214D4EA87 @default.
- Q66078394 P3098 Q66078394-2A1A8021-06CC-44E6-AA7B-DD9696E94D29 @default.
- Q66078394 P31 Q66078394-E9D354A8-378B-4C04-83C7-2E176FA882E7 @default.
- Q66078394 P4135 Q66078394-0C0FC3EB-023E-45DD-A4F2-E0F39C6654BA @default.
- Q66078394 P4844 Q66078394-7ABF1004-99D1-41F4-AF60-E444F0D20239 @default.
- Q66078394 P580 Q66078394-5A0A2E46-A10D-456E-9B39-FD9695A97B49 @default.
- Q66078394 P582 Q66078394-D78D74F3-FE8D-424F-A98F-82C375F10B63 @default.
- Q66078394 P6099 Q66078394-1C4089B5-1ECC-4B43-852A-4984821A3FAE @default.
- Q66078394 P8363 Q66078394-F1D49276-6697-4445-AADD-6B7A55FC4D1A @default.
- Q66078394 P1050 Q41112 @default.
- Q66078394 P1132 "+380" @default.
- Q66078394 P1476 "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia" @default.
- Q66078394 P17 Q16 @default.
- Q66078394 P17 Q212 @default.
- Q66078394 P17 Q219 @default.
- Q66078394 P17 Q28 @default.
- Q66078394 P17 Q29 @default.
- Q66078394 P17 Q30 @default.
- Q66078394 P17 Q36 @default.
- Q66078394 P17 Q403 @default.
- Q66078394 P2899 "+18" @default.
- Q66078394 P3098 "NCT02970305" @default.
- Q66078394 P31 Q30612 @default.
- Q66078394 P4135 "+55" @default.
- Q66078394 P4844 Q7194603 @default.
- Q66078394 P580 "2016-11-01T00:00:00Z" @default.
- Q66078394 P582 "2019-05-01T00:00:00Z" @default.
- Q66078394 P6099 Q42824440 @default.
- Q66078394 P8363 Q78089383 @default.